SPY760.30+0.06%QQQ690.20−0.03%BTC/USD74,392.70+0.94%DIA524.58+0.03%GLD365.20+0.01%TLT80.95+0.04%

Charles River Laboratories International Inc

CRLNYSE

Trade with Public

$342.69

-3.11-0.9%

Last update: Nov 11, 4:28 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Earnings: Q3 2026 Earnings were released on Wed Nov 4th, before the market open

Conference Call: The most recent conference call started at 9:00 AM, 7 days ago

Click to view the webcast

M&A: Frontage Holdings Corporation and DMPK announced it will sell assets to Charles River (CRL) on Monday, November 9, 2026 for $470M paid in cash

Earnings: Q3 2026 Earnings were released on Wed Nov 4th, before the market open

Conference Call: The most recent conference call started at 9:00 AM, 7 days ago

Click to view the webcast

M&A: Frontage Holdings Corporation and DMPK announced it will sell assets to Charles River (CRL) on Monday, November 9, 2026 for $470M paid in cash

Charles River (CRL) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Charles River (CRL) stock.

Analyst Consensus — 16 Analysts

9Buy

4Hold

3Sell

# Analysts16

Latest Upgrades and Downgrades for Charles River Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	UBS	Kevin Caliendo	PT Raise	Buy	$357→$387
—	RBC Capital	Ryan Halsted	PT Raise	Outperform	$322→$352
—	Barclays	Luke Sergott	PT Raise	Overweight	$330→$375
—	Evercore ISI Group	Ross Muken	PT Raise	Outperform	$330→$400
—	Morgan Stanley	Ricky Goldwasser	PT Raise	Overweight	$300→$340
—	UBS	Kevin Caliendo	Reinstates	Buy	$357
—	Jefferies	David Windley	PT Raise	Buy	$305→$340
—	Deutsche Bank	Justin Bowers	PT Raise	Buy	$300→$320
—	TD Cowen	Charles Rhyee	PT Raise	Buy	$300→$325
—	Evercore ISI Group	Ross Muken	PT Raise	Outperform	$320→$330
—	RBC Capital	Ryan Halsted	PT Raise	Outperform	$282→$322
—	Barclays	Luke Sergott	PT Raise	Overweight	$300→$330
—	Mizuho	Ann Hynes	PT Raise	Neutral	$264→$295
—	Baird	Eric Coldwell	PT Raise	Outperform	$291→$334
—	Evercore ISI Group	Ross Muken	PT Raise	Outperform	$300→$320
—	TD Cowen	Charles Rhyee	PT Raise	Buy	$235→$300
—	Morgan Stanley	Ricky Goldwasser	PT Raise	Overweight	$260→$300
—	RBC Capital	Ryan Halsted	PT Raise	Outperform	$215→$282
—	Evercore ISI Group	Ross Muken	PT Raise	Outperform	$260→$300
—	JP Morgan	Casey Woodring	Upgrade	Neutral→Overweight	$180→$310

Charles River Laboratories International Inc

Charles River (CRL) Stock Price Target 2026

Latest Upgrades and Downgrades for Charles River Stock

Charles River (CRL) Stock Price Target 2026

Latest Upgrades and Downgrades for Charles River Stock

Analyst Ratings News

Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says

PRO
UBS Maintains Buy on Charles River, Raises Price Target to $387

PRO
RBC Capital Maintains Outperform on Charles River, Raises Price Target to $352

PRO
Barclays Maintains Overweight on Charles River, Raises Price Target to $375

PRO
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400

PRO
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340

People Also Watch

People Also Watch

Analyst Ratings News

Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says

PRO
UBS Maintains Buy on Charles River, Raises Price Target to $387

PRO
RBC Capital Maintains Outperform on Charles River, Raises Price Target to $352

PRO
Barclays Maintains Overweight on Charles River, Raises Price Target to $375

PRO
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400

PRO
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340

Charles River Laboratories International Inc

Charles River (CRL) Stock Price Target 2026

Latest Upgrades and Downgrades for Charles River Stock

Charles River (CRL) Stock Price Target 2026

Latest Upgrades and Downgrades for Charles River Stock

Analyst Ratings News

Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says

PROUBS Maintains Buy on Charles River, Raises Price Target to $387

PRORBC Capital Maintains Outperform on Charles River, Raises Price Target to $352

PROBarclays Maintains Overweight on Charles River, Raises Price Target to $375

PROEvercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400

PROMorgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340

People Also Watch

People Also Watch

Analyst Ratings News

Charles River Laboratories Recent $470 Million Deal an 'Attractive Strategic Addition,' Analyst Says

PROUBS Maintains Buy on Charles River, Raises Price Target to $387

PRORBC Capital Maintains Outperform on Charles River, Raises Price Target to $352

PROBarclays Maintains Overweight on Charles River, Raises Price Target to $375

PROEvercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400

PROMorgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340

PRO
UBS Maintains Buy on Charles River, Raises Price Target to $387

PRO
RBC Capital Maintains Outperform on Charles River, Raises Price Target to $352

PRO
Barclays Maintains Overweight on Charles River, Raises Price Target to $375

PRO
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400

PRO
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340

PRO
UBS Maintains Buy on Charles River, Raises Price Target to $387

PRO
RBC Capital Maintains Outperform on Charles River, Raises Price Target to $352

PRO
Barclays Maintains Overweight on Charles River, Raises Price Target to $375

PRO
Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $400

PRO
Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to $340